VIBATIV is the only once-daily in vitro bactericidal antibiotic with a dual mechanism of action indicated for infections due to S. aureus, including MRSA and MSSA. VIBATIV is indicated for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates.
Astellas Pharma created a breakthrough product in the area of treatment for MRSA and cSSSI. With a unique dual mechanism of action (MOA), Vibativ could more efficaciously fight severe infections caused by methicillin-resistent staphylococci in adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP).
Astellas wanted this campaign to be aggressive and arresting. The focus was to be around the dual MOA.
The inspiration behind this concept is Cerberus from greek mythology. Cerberus, called the "hound of Hades", is the multi-headed dog that guards the gates of the underworld to prevent the dead from leaving. In art, Cerberus is most commonly depicted with two dog heads which represents the dual MOA of Vibativ.
Digital app for iOS and Android
The app featured patient profiles in fighting MRSA and cSSSI, and the navigation was broken down into four main patient categories: inpatient, outpatient, hospital outpatient and home health patient.